Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mednax

Related MD
MEDNAX Buys Pediatric Cardiology Practice In Virginia For Undisclosed Terms
MEDNAX Agrees To Buy Cardon Outreach For $400 Million

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mednax (NYSE: MD), and raised its price target from $81.00 to $88.00.

Jefferies noted, “MD is one of our top picks given our belief that the company's push to aggressively expand its anesthesiology business (which we expect mgmt to highlight at today's analyst day) will drive robust growth over the next several years that is not yet adequately reflected in the stock's valuation. Our positive bias is also driven by MD's highly defensive (i.e., benign) reimbursement outlook. Reiterate Buy/PT to $88.”

Mednax closed on Tuesday at $75.29.

Latest Ratings for MD

Aug 2016JefferiesMaintainsBuy
Aug 2016CitigroupMaintainsNeutral
Jul 2016JP MorganMaintainsOverweight

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (MD)

View Comments and Join the Discussion!